Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 10-Q: Q3 2024 Earnings Report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Highbridge Capital Management, LLC(9.99%)
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 10-Q: Q2 2024 Earnings Report
Matinas BioPharma | 8-K: Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma | 8-K: Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Matinas BioPharma | 10-Q: Q1 2024 Earnings Report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 424B5: Prospectus
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 10-K: FY2023 Annual Report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 8-K: Current report
Matinas BioPharma | 8-K: Current report